Evidence map›Paper›PMID 23128089›Full record

ReviewMolecules (Basel, Switzerland)2012

Forward chemical genetics in yeast for discovery of chemical probes targeting metabolism.

Robert St Onge, Ulrich Schlecht, Curt Scharfe, Marie Evangelista

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell-molecular insights about chemoresistance.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Robert St OngeDepartment of Biochemistry, Stanford Genome Technology Center, Stanford University, Stanford, CA 94305, USA. bstonge@stanford.edu
Ulrich Schlecht
Curt Scharfe
Marie Evangelista
Stanford University · US

Funding

WHOLE YEAST GENOME TRANSCRIPTIONAL AND FUNCTIONAL GENE MAPS--A FEASIBILITY STUDYP01HG000205 · NHGRI · STANFORD UNIVERSITY · PI DAVIS, RONALD WAYNE, HOWE, ROGER THOMAS · 1990 to 2016
$120.9M
Technology to Identify and Assay Chemical Genomic ProbesR01HG003317 · NHGRI · STANFORD UNIVERSITY · PI DAVIS, RONALD WAYNE · 2004 to 2012
$9.1M
Discovery of Biomarkers in Human Mitochondrial DiseasesR01EY016240 · NEI · STANFORD UNIVERSITY · PI DAVIS, RONALD WAYNE · 2006 to 2011
$3.6M
Identification of Small-Molecule Inhibitors of Protein-Protein InteractionsR21HG005785 · NHGRI · STANFORD UNIVERSITY · PI DAVIS, RONALD WAYNE · 2010 to 2011
$440k
NEI NIH HHS R01 EY016240NEI NIH HHS R01EY016240NHGRI NIH HHS 2R01HG003317-05NHGRI NIH HHS P01 HG000205NHGRI NIH HHS R01 HG003317NHGRI NIH HHS R21 HG005785NHGRI NIH HHS R21HG005785-01
6 · The paper itself

Abstract

The many virtues that made the yeast Saccharomyces cerevisiae a dominant model organism for genetics and molecular biology, are now establishing its role in chemical genetics. Its experimental tractability (i.e., rapid doubling time, simple culture conditions) and the availability of powerful tools for drug-target identification, make yeast an ideal organism for high-throughput phenotypic screening. It may be especially applicable for the discovery of chemical probes targeting highly conserved cellular processes, such as metabolism and bioenergetics, because these probes would likely inhibit the same processes in higher eukaryotes (including man). Importantly, changes in normal cellular metabolism are associated with a variety of diseased states (including neurological disorders and cancer), and exploiting these changes for therapeutic purposes has accordingly gained considerable attention. Here, we review progress and challenges associated with forward chemical genetic screening in yeast. We also discuss evidence supporting these screens as a useful strategy for discovery of new chemical probes and new druggable targets related to cellular metabolism.

Indexed as

Drug Screening Assays, AntitumorAnimalsAntimetabolites, AntineoplasticGlycolysisHumansLeucovorinMethotrexateMolecular Targeted TherapyMutagenesisNeoplasmsPhenotypeSaccharomyces cerevisiaeAntimetabolites, AntineoplasticLeucovorinMethotrexate

Identifiers

PMID23128089
PMCPMC3539408
OpenAlexW2044642858

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.